Cocrystal Pharma's CC-42344 Cleared for UK Phase 2a Trial; Company Disputes CRO Results
COCP sits 47% above its 52-week low of $0.859.
Summary
Cocrystal Pharma received approval from the UK MHRA to proceed with a Phase 2a human challenge trial for its antiviral candidate, CC-42344, marking a positive advancement in its pipeline. Concurrently, the company announced it is disputing parts of a Contract Research Organization's (CRO) reported study results, introducing a new element of uncertainty and potential risk regarding clinical data integrity. While the headline also mentioned Q1 adjusted loss per share of $0.17, this financial update was already disclosed in yesterday's Q1 earnings report and 10-Q filing. The regulatory approval is a material positive for the clinical-stage biotech, but the CRO dispute could temper investor enthusiasm and warrants close monitoring, especially given the company's previously reported going concern warning and urgent need for capital.
At the time of this announcement, COCP was trading at $1.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $16.5M. The 52-week trading range was $0.86 to $2.67. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Wiseek News.